Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis
- 1 January 2006
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 24 (1) , 4-12
- https://doi.org/10.1016/j.urolonc.2005.06.020
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- Skeletal Complications in Men with Prostate Cancer: Effects on Quality-of-Life Outcomes throughout the Continuum of CareEuropean Urology Supplements, 2004
- Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate CancerClinical Cancer Research, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Osteoporosis during Continuous Androgen Deprivation: Influence of the Modality and Length of TreatmentEuropean Urology, 2003
- Immediate dual energy X‐ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulationBJU International, 2003
- Low bone mineral density in hormone-na ve men with prostate carcinomaCancer, 2001
- Metastatic bone disease: clinical features, pathophysiology and treatment strategiesCancer Treatment Reviews, 2001
- Osteoporosis Due to Cancer Treatment: Pathogenesis and ManagementJournal of Clinical Oncology, 2000
- Androgen deprivation therapy for prostate cancer results in significant loss of bone densityUrology, 1999
- Long-Term (15 Years) Results After Radical Prostatectomy For Clinically Localized (Stage T2c Or Lower) Prostate CancerJournal of Urology, 1994